A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

In this trial, a 24-week regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin was noninferior to standard care for rifampin-resistant tuberculosis.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-12, Vol.387 (25), p.2331-2343
Hauptverfasser:	Nyang’wa, Bern-Thomas, Berry, Catherine, Kazounis, Emil, Motta, Ilaria, Parpieva, Nargiza, Tigay, Zinaida, Solodovnikova, Varvara, Liverko, Irina, Moodliar, Ronelle, Dodd, Matthew, Ngubane, Nosipho, Rassool, Mohammed, McHugh, Timothy D., Spigelman, Melvin, Moore, David A.J., Ritmeijer, Koert, du Cros, Philipp, Fielding, Katherine
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adolescent Adult Adverse events Antibiotics Antitubercular Agents - administration & dosage Antitubercular Agents - adverse effects Antitubercular Agents - pharmacology Antitubercular Agents - therapeutic use Clinical trials Drug dosages Drug Therapy, Combination Global Health Humans Infectious Disease Infectious Disease General Laboratories Linezolid Linezolid - administration & dosage Linezolid - adverse effects Linezolid - therapeutic use Moxifloxacin Moxifloxacin - administration & dosage Moxifloxacin - adverse effects Moxifloxacin - therapeutic use Rifampin Rifampin - adverse effects Rifampin - pharmacology Statistical analysis Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Pulmonary - drug therapy Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this trial, a 24-week regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin was noninferior to standard care for rifampin-resistant tuberculosis.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2117166